International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064




Downloads: 0 | Views: 144

Informative Article | Surgery | Indonesia | Volume 11 Issue 11, November 2022 | Rating: 4.8 / 10


Characteristic of Ameloblastoma in Oral and Maxillofacial Surgery Hasan Sadikin Hospital: 1 Year Retrospective Study

Rachendra Pratama [3] | Andri Hardianto [3] | Eka Marwansyah Oli'I


Abstract: Introduction: Ameloblastoma is the most common odontogenic tumour. Ameloblastoma is a borderline tumour because ameloblastoma is a benign but locally aggressive tumour with a high recurrence rate if the excision is not complete. The principle of treatment for ameloblastoma is excision all the tumour. Method: This study is a retrospective study with 76 patients diagnosed with ameloblastoma during 2019-2020. Data taken from each patient were gender, age, radiological features, the histopathological diagnosis of the location of ameloblastoma, management, defects, reconstruction. Result: A total of 35 patients were plexiform ameloblastoma, 22 patients with follicular ameloblastoma, 3 patients with mixed plexiform and follicular ameloblastoma and 16 patients with unspecified ameloblastoma. 30 patients were treated radically, while 16 patients were treated conservatively. Discussion: Radical treatment is more often used to reduce recurrence rates, whereas conservative measures are indicated in children and adolescents, as well as adult patients with unilocular ameloblastoma types. Conclusion: The most characteristic of ameloblastoma is plexiform ameloblastoma and located in the mandible. Ameloblastoma performed radically and reconstructed with an AO plate.


Keywords: Ameloblastoma, Characteristic, Epidemiology


Edition: Volume 11 Issue 11, November 2022,


Pages: 75 - 81



How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link


Verification Code will appear in 2 Seconds ... Wait

Top